AVAV
AeroVironment, Inc.Thesis. AVAV is the purest listed play on loitering munitions, counter-UAS and battlefield autonomy, with 133% revenue growth and a fresh $500M Domestic Shield IDIQ underpinning the demand story. The stock has been cut 61% from its high on integration-driven GAAP losses and serial EPS misses, but the order book (Titan MS, Puma LE for Germany) and 89% institutional base argue the derating has overshot. We accumulate ahead of the investor day, sizing for volatility.
Scoreboard
At $162.53 AVAV sits 61% below its $417.86 52-week high and just 20% above the $135.20 low — the 10th percentile of its annual range — capitalizing the equity at $8.23bn (EV $8.40bn). The price trades under both the 50-day ($174.23) and 200-day ($253.33) averages, a textbook downtrend, yet the $258.61 consensus target implies 59% upside and even the $166 street low is above spot. The gap between a battered tape and an intact sell-side is the setup.
QoQ Changes
Fiscal Q4 (period ended 2026-04-30) revenue jumped to $641.6m from $408.0m the prior quarter (+57% QoQ), the BlueHalo scale finally showing, while basic EPS printed $1.26 versus -$3.15. On a Finnhub calendar basis AVAV delivered $1.84 adjusted EPS, a +23.2% beat that broke a three-quarter miss streak.
Gross margin recovered to 31.6% of sales in Q4 ($202.6m on $641.6m) from a compressed 24.2% in the January quarter, and operating income swung positive to $56.9m (8.9% margin) from -$27.7m. Trailing-twelve-month blended margins remain thin — 25.3% gross, 2.8% operating — reflecting purchase-accounting and integration drag.
FCF margin is negative at -12.7% and FCF yield is -3.1%, so the franchise is consuming cash as it scales working capital against a surging backlog. Until loitering-munition and Titan deliveries convert, cash generation stays a show-me item.
The company holds $632.3m cash ($12.54/share) against $834.8m debt, leaving a net debt position of $202.5m. Liquidity is comfortable — current ratio 4.30x, quick ratio 3.47x — but debt/equity screens optically high at 18.97 on a low book denominator.
Shares fetch 35.2x forward earnings, 4.16x sales and a punchy 43.1x EV/EBITDA — a growth multiple, not a value one, despite the drawdown. PEG of 1.57 and P/B of 1.89 leave the name fairly-to-fully priced on current numbers, with the bull case resting on out-year margin normalization.
Recent actions are order-book, not restructuring: a three-year $500m Domestic Shield IDIQ from JIATF-401, an $80.5m Titan MS delivery order, and a ~$30.9m Puma AE/LE award for Germany's LARUS program via NSPA. An investor day is pending and flagged by RBC as a likely mid-term framework reset.
Ownership & Insider Activity
Institutions own 89.1% (BlackRock 9.8%, State Street 4.5%, Vanguard entities ~6.5% combined), while insiders hold a thin 0.77% — a governance-light float. Finnhub Form 4 data shows persistent, mechanical insider selling: director Stephen Page sold in every month from January to June 2026 (e.g., -1,000 shares at $377.62 on 2026-01-15, then -250 at $174.41 on 2026-06-15), and Kevin McDonnell dumped -879 shares at $267.60, netting roughly -$7.5m of open-market sales with zero insider buys. The absence of any insider accumulation into a 61% drawdown, plus a 12.6% short interest (3.85 days to cover), signals no smart-money conviction at these levels — a caution flag against the bullish street.
Recent Insider Transactions
| Date | Insider | Position | Shares | Value |
|---|---|---|---|---|
| 2026-07-02 | DAVIDSON PHILLIP S | Director | 1,177 | $0.00 |
| 2026-07-02 | LONG MARY BETH | Director | 1,177 | $0.00 |
| 2026-07-02 | LYNN WILLIAM III | Director | 892 | $0.00 |
| 2026-07-02 | STEVENSON TRACE E | Officer | 2,406 | $0.00 |
| 2026-07-02 | VOTEL JOSEPH L. | Director | 1,308 | $0.00 |
| 2026-07-02 | MCDANIEL CLUM MARY ELIZABETH | Officer | 1,210 | $0.00 |
Earnings Quality
| Period | Actual EPS | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
| 2026-06-30 Q4 | $1.84 | $1.49 | +$0.35 | +23.18% |
| 2026-03-31 Q3 | $0.64 | $0.71 | $-0.07 | -9.26% |
| 2025-12-31 Q2 | $0.44 | $0.79 | $-0.35 | -44.56% |
| 2025-09-30 Q1 | $0.32 | $0.38 | $-0.06 | -15.12% |
AVAV beat consensus in just 1 of the last 4 quarters (25% beat rate) with an average surprise of -11.4%, including a -44.6% air-pocket in the December 2025 quarter — a poor execution track record that justified analyst skepticism.
The trajectory is inflecting: after three straight misses the June-quarter +23.2% beat suggests guidance was finally reset low enough and integration costs are peaking, an early sign of analyst miscalibration to the upside.
Analyst Action
| Month | Distribution | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|---|
| 2026-07 | 9 | 14 | 4 | 0 | 0 | |
| 2026-06 | 8 | 14 | 4 | 0 | 0 | |
| 2026-05 | 8 | 13 | 4 | 0 | 0 | |
| 2026-04 | 8 | 13 | 4 | 0 | 0 |
The Finnhub rating series shows steady bullish drift — Strong Buy rose from 8 to 9 and Buy from 13 to 14 between April and July 2026, with Hold flat at 4 and zero Sell/Strong Sell throughout. Consensus recommendation mean sits at 1.6 ('buy') across 18 analysts.
Momentum is modestly bullish — ratings composition is grinding higher even as the price falls, though no upgrades/downgrades hit in the last 15 days.
Seven Essential Metrics
TTM profit margin -13.4%, operating margin just 2.8%, ROE -10.0% — GAAP losses from purchase-accounting and integration drag.
Revenue growth of 133% (BlueHalo-driven) with Q4 sales at $641.6m; earnings growth n/a on negative base.
FCF margin -12.7% and FCF yield -3.1% — the business is burning cash while scaling backlog.
Net debt of -$202.5m and debt/equity of 18.97 optically, but current ratio 4.30x cushions near-term risk.
Beta 1.395, 12.6% short interest, sitting at the 10th percentile of its 52-week range — high volatility, elevated drawdown risk.
35.2x forward P/E, 43.1x EV/EBITDA and 4.16x P/S price in flawless out-year margin recovery.
BlueHalo stock consideration expanded the share count; no buyback, and insiders are net sellers (~-$7.5m).
AVAV pays no dividend, reinvesting into autonomy, C-UAS and directed-energy capacity.
Competitive Snapshot
| Company | EBITDA Margin | 3Y Rev CAGR | FCF Margin | Leverage | Fwd P/E |
|---|---|---|---|---|---|
KTOS Kratos Defense & Security | ~10% | ~15% | ~2% | Net cash | ~70x |
LHX L3Harris Technologies | ~22% | ~8% | ~12% | ~3x | ~19x |
LMT Lockheed Martin | ~14% | ~4% | ~7% | ~1.5x | ~17x |
RCAT Red Cat Holdings | negative | ~40% | negative | Net cash | n/a |
AVAV commands the fastest top-line growth in its cohort (133% reported, merger-inflated) but the weakest current profitability, mirroring hyper-growth peer KTOS more than the diversified primes LHX/LMT. Against the primes it trades at a steep 35x forward premium versus ~17-19x, a multiple only defensible if loitering-munition and C-UAS demand lets margins converge toward prime levels. Versus small-cap drone names like RCAT it offers battlefield-proven scale and a $500m IDIQ backbone — a quality edge that justifies some premium within the emerging-drone bucket.
Business & Strategy
Two segments: Autonomous Systems (small/medium UAS like Puma, loitering munitions/Switchblade, counter-UAS such as Titan) and Space, Cyber & Directed Energy (digital beamforming, laser comms, phased-array for hypersonic telemetry, directed energy). The BlueHalo combination materially widened the space/cyber/DE footprint and drove the 133% revenue step-up.
Primary customers are the U.S. Department of Defense and allied governments — e.g., USAF Global Strike Command (Titan), the German Bundeswehr via NATO's NSPA (Puma).
Revenue spans product deliveries (drones, munitions, C-UAS hardware) plus IDIQ delivery orders and sustainment/services; the new $500m three-year Domestic Shield IDIQ anchors recurring Titan MS order flow.
Cost is dominated by production materials/electronics, skilled engineering headcount (3,991 employees; ~$495k revenue/employee), and integration/purchase-accounting amortization from BlueHalo.
AVAV's moat is battlefield-proven, program-of-record status across Puma, Switchblade and Titan — hard-won qualification, DoD trust and switching costs that emerging drone rivals cannot replicate quickly. Directed-energy and beamforming IP add optionality as counter-drone warfare scales globally.
Monetary-Policy Sensitivity
- Long-duration, no-dividend growth equity — discount-rate sensitive
- High beta (1.40) amplifies risk-on multiple expansion
- Cash burn makes cheaper financing supportive
As an unprofitable, high-multiple growth name, AVAV's valuation is disproportionately driven by the discount applied to out-year cash flows, so easing is a tailwind for the multiple. That said, defense demand is budget- rather than rate-driven, so rate moves affect the valuation lens more than the fundamentals.
SWOT Analysis
- Program-of-record franchises (Puma, Switchblade, Titan) with proven combat pedigree
- 133% revenue growth and a fresh $500m Domestic Shield IDIQ backlog
- 89% institutional ownership and strong liquidity (4.30x current ratio)
- Pure-play exposure to loitering munitions and counter-UAS, the hottest defense sub-themes
- GAAP unprofitable — -13.4% profit margin, negative FCF
- 1-of-4 EPS beat rate with -11.4% average surprise
- Persistent insider selling (~-$7.5m, zero buys)
- Expensive at 35x forward and 43x EV/EBITDA
- FY2027 defense budget's Defense Autonomous Warfare Group and $1.5tn autonomy opportunity
- NATO reamament and allied Puma/Titan exports (Germany LARUS)
- BlueHalo synergies in space, cyber and directed energy
- Investor day as a catalyst to reset the mid-term margin framework
- Integration execution risk keeping margins depressed
- 12.6% short interest and high beta driving drawdowns
- Program lumpiness and government budget/CR timing
- Emerging low-cost drone competitors compressing pricing
Catalysts & Event Risks
- Q3 2026Investor Day
Management expected to lay out a mid-term organic growth and margin framework RBC calls potentially 'constructive'.
- Q3 2026Fiscal Q1 2027 earnings
First clean post-integration print; a second consecutive beat would validate the June inflection.
- 2026-07-08Domestic Shield delivery orders
Incremental Titan MS orders under the new $500m IDIQ could flow near-term and lift the backlog narrative.
- Q3 2026NATO/allied awards
Follow-on Puma and loitering-munition orders from European rearmament post-NATO summit.
- Q4 2026FY2027 defense budget/DAWG
Appropriations detail on the Defense Autonomous Warfare Group directly targets AVAV's addressable market.
The near-term tape is event-rich: an investor day plus a clean Q1 print could re-rate sentiment quickly if execution holds. Contract cadence under Domestic Shield is the most tangible, self-help catalyst.
Technical Analysis
AVAV is in a clear downtrend, trading below its 50-day ($174.23) and well under its 200-day ($253.33), and sitting at the 10th percentile of its 52-week range. The $135.20 low is the line in the sand; a break there opens air below, while reclaiming the 50-day near $174 is the first sign of repair. With the stock -8.1% on the day on above-average volume (2.24m vs 1.56m), the price action is still distributive. Risk-reward improves for accumulators only because downside to support (~17%) is now smaller than the 29% path to our target — but this is a knife best caught in tranches.
Verdict
Macro context. The backdrop is unusually favorable: NATO rearmament, a FY2027 U.S. defense budget elevating autonomous warfare (the new DAWG line item), and Ukraine-proven demand for cheap loitering munitions and counter-drone systems all expand AVAV's addressable market. The offset is a high-multiple growth name exposed to rate and risk sentiment during integration.
AVAV is the cleanest public expression of the loitering-munition and counter-UAS super-cycle, and the 61% drawdown from its high has repriced a great franchise to a merely-expensive one just as execution appears to inflect (June's +23% beat, $500m Domestic Shield IDIQ, German Puma order). The bear case is real — cash burn, thin margins, relentless insider selling and a 35x multiple leave no room for error — but the demand signal, 89% institutional base and event-rich catalyst calendar tilt the odds. We rate the shares ACCUMULATE with a $210 target (29% upside), building the position in tranches into support and sizing for the volatility.
Data source: Yahoo Finance / yfinance · fetched 7/8/2026, 10:17:32 AM